CARSON CITY, Nev., July 10, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of ...
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...
Boston, Massachusetts--(Newsfile Corp. - April 29, 2025) - Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, ...
MILAN, Aug. 28, 2025 (GLOBE NEWSWIRE) — AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced ...
Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Repare Therapeutics Inc.
New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie (ABBV)'s growing ADC portfolio designed to target ...
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, ...
Hosted on MSN
Context Therapeutics to Present New Data on Two Bispecific T Cell Engagers at SITC 2025
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced that it will present new clinical and preclinical data at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback